Inflammasome Activation in Neurodegenerative Diseases

Inflammasomes are multi-protein platforms that sense pathogenic protein aggregates and cellular stress in the central nervous system, driving the maturation of pro-inflammatory cytokines and inflammatory cell death. In microglia, resident immune cells of the brain, activation of caspase-1 within NLRP3 and related inflammasomes leads to release of interleukin-1β and interleukin-18, amplifying synaptic dysfunction and neuronal injury. Pyroptosis, a gasdermin D-mediated lytic pathway, contributes to neurodegeneration in Alzheimer’s, Parkinson’s and related disorders. Emerging studies highlight fluid biomarkers of inflammasome activation, mechanisms regulating cholesterol-dependent assembly and transcriptional control of inflammatory pathways. Targeting inflammasome components offers promising diagnostic and therapeutic avenues against chronic neuroinflammation and cognitive decline.

Research from Nature Portfolio

Ultra-sensitive single-molecule assays have revealed that extracellular ASC specks, the polymeric assemblies of apoptosis-associated speck-like protein containing a CARD, are elevated in the blood, cerebrospinal fluid and post-mortem brain of early-stage Alzheimer’s and Parkinson’s patients. Morphological alterations in ASC specks, combined with measurements of aggregated β-amyloid, phosphorylated tau and α-synuclein, form composite ratios that distinguish patients from healthy controls with high accuracy, paving the way for minimally invasive diagnostics and trial biomarkers.

Pharmacological inhibition of caspase-1 with a blood–brain barrier-permeable small molecule reverses cognitive deficits and neuropathology in a transgenic model of Alzheimer’s disease. Treatment normalises episodic and spatial memory, reduces amyloid-β deposition, attenuates neuroinflammation and restores synaptic markers. Genetic ablation of caspase-1 yields comparable protection, providing in vivo proof-of-concept for targeting inflammasome-mediated pathways in neurodegeneration.

Inflammasome Activation in Neurodegenerative Diseases publication trend

The graph below shows the total number of articles in inflammasome activation in neurodegenerative diseases across all publications each year (not limited to Nature Index journals).

Technical terms

Inflammasome: Multi-protein complex that activates caspase-1 to process pro-inflammatory cytokines and induce pyroptosis.

NLRP3: Pattern recognition receptor (NOD-like receptor family, pyrin domain containing 3) that nucleates inflammasome assembly in response to stress and protein aggregates.

ASC speck: Polymerised adaptor protein (apoptosis-associated speck-like protein containing a CARD) that scaffolds inflammasome complexes.

Pyroptosis: Inflammatory form of programmed cell death mediated by gasdermin D pore formation.

Microglia: Innate immune cells of the central nervous system responsible for surveillance, phagocytosis and inflammatory signalling.

Caspase-1: Protease activated within the inflammasome that cleaves pro-interleukin-1β and pro-interleukin-18 into their active forms and triggers pyroptosis.

References

1. ASC specks as a single-molecule fluid biomarker of inflammation in neurodegenerative diseases. Nature Communications (2024).
2. Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer’s disease mouse model. Nature Communications (2018).
3. Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis. Translational Neurodegeneration (2023).
4. Nanoligomers targeting NF-κB and NLRP3 reduce neuroinflammation and improve cognitive function with aging and tauopathy. Journal of Neuroinflammation (2024).